- Home
- LXEO
as 09-12-2025 10:17am EST
Stocks
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 257.0M | IPO Year: | 2023 |
| Target Price: | $15.29 | AVG Volume (30 days): | 388.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.45 - $11.72 | Next Earning Date: | 08-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Lexeo Therapeutics Inc. (LXEO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Adler Eric | LXEO | Chief Medical Officer | Aug 18 '25 | Sell | $4.67 | 608 | $2,838.14 | 67,073 | |
| Robertson Jenny | LXEO | Chief Legal Officer | Aug 18 '25 | Sell | $4.67 | 542 | $2,530.06 | 62,556 | |
| Townsend Richard Nolan | LXEO | Chief Executive Officer | Aug 18 '25 | Sell | $4.67 | 2,735 | $12,766.98 | 220,058 | |
| See Tai Sandi | LXEO | Chief Development Officer | Aug 18 '25 | Sell | $4.67 | 382 | $1,783.18 | 58,860 | |
| Otero Jose Manuel | LXEO | Chief Technical Officer | Aug 18 '25 | Sell | $4.67 | 2,848 | $13,294.46 | 60,372 |
Latest Lexeo Therapeutics Inc. News
LXEO Breaking Stock News: Dive into LXEO Ticker-Specific Updates for Smart Investing
MT Newswires
3 months ago
Lexeo Therapeutics Partners with PXV Funds, venBio on New Cardiac RNA Therapeutics Venture
GlobeNewswire
3 months ago
Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics
MT Newswires
3 months ago
Lexeo Therapeutics Registers Share Offering on Behalf of Selling Stockholders
Simply Wall St.
3 months ago
June 2025 Penny Stocks With Promising Potential
GlobeNewswire
4 months ago
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases
MT Newswires
4 months ago
Chardan Adjusts Price Target on Lexeo Therapeutics to $20 From $22, Maintains Buy Rating
GlobeNewswire
4 months ago
Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights
Simply Wall St.
4 months ago
Undervalued Penny Stocks To Consider In May 2025
Compare LXEO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LXEO Lexeo Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.